RLX Technology Inc vs Twist Bioscience Corp — how do they compare? RLX Technology Inc trades at $1.72 (market cap $2.10B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 4.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and Twist Bioscience Corp for 27 Days on average.
| RLX | TWST | |
|---|---|---|
Market Cap | $2.10B | $10.08B |
Volume | 1,079,706 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $205.00 |
52-Week Low | $1.68 | $25.45 |
Typical Hold Time | 34 Days | 27 Days |
Enterprise Value | $832.26M | $10.01B |
Dividend Yield | 5.81% | — |
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, near its 52-week low of $1.67, with bearish technical signals from moving averages. The company reported strong 2025 fundamentals with $921.87M net income and 21.87% net margin, though recent quarters show earnings misses. International expansion drives growth, with 70% of revenue now from overseas markets following European acquisitions.
The stock presents a value opportunity with discounted valuation multiples (P/E 15.46, P/B 0.91) but faces headwinds from recent earnings underperformance and bearish technical momentum. Key risks include margin compression and regulatory uncertainty in the e-vapor industry, while analyst sentiment remains neutral with 100% hold rating.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →